Sei Investments Co. bought a new position in Travere Therapeutics, Inc. (NASDAQ:RTRX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 50,382 shares of the biopharmaceutical company’s stock, valued at approximately $930,000. Sei Investments Co. owned approximately 0.10% of Travere Therapeutics as of its most recent filing with the SEC.
Other institutional investors also recently bought and sold shares of the company. American International Group Inc. boosted its stake in Travere Therapeutics by 3.5% during the 2nd quarter. American International Group Inc. now owns 25,361 shares of the biopharmaceutical company’s stock valued at $518,000 after purchasing an additional 848 shares during the last quarter. AJO LP raised its holdings in Travere Therapeutics by 97.9% during the second quarter. AJO LP now owns 14,847 shares of the biopharmaceutical company’s stock valued at $303,000 after acquiring an additional 7,343 shares during the period. Bank of Montreal Can raised its holdings in Travere Therapeutics by 1.8% during the second quarter. Bank of Montreal Can now owns 197,179 shares of the biopharmaceutical company’s stock valued at $3,972,000 after acquiring an additional 3,490 shares during the period. Marshall Wace LLP bought a new stake in Travere Therapeutics during the second quarter valued at about $2,020,000. Finally, Vanguard Group Inc. raised its holdings in Travere Therapeutics by 15.4% during the second quarter. Vanguard Group Inc. now owns 2,970,844 shares of the biopharmaceutical company’s stock valued at $60,636,000 after acquiring an additional 396,250 shares during the period.
Shares of NASDAQ:RTRX opened at $27.26 on Friday. Travere Therapeutics, Inc. has a 1 year low of $8.98 and a 1 year high of $24.96. The business has a 50 day simple moving average of $25.22 and a two-hundred day simple moving average of $21.02. The firm has a market capitalization of $1.39 billion, a PE ratio of -12.92 and a beta of 0.67. The company has a debt-to-equity ratio of 0.66, a current ratio of 7.23 and a quick ratio of 7.14.
Travere Therapeutics (NASDAQ:RTRX) last announced its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.59) by $0.15. Travere Therapeutics had a negative return on equity of 36.38% and a negative net margin of 49.13%. Equities research analysts expect that Travere Therapeutics, Inc. will post -1.62 EPS for the current fiscal year.
In related news, SVP Elizabeth E. Reed sold 2,500 shares of the company’s stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $23.62, for a total value of $59,050.00. Following the completion of the sale, the senior vice president now directly owns 30,431 shares of the company’s stock, valued at $718,780.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Peter Heerma sold 2,188 shares of the stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $19.35, for a total transaction of $42,337.80. The disclosure for this sale can be found here. Insiders have sold 49,063 shares of company stock valued at $1,135,169 in the last 90 days. Company insiders own 4.63% of the company’s stock.
A number of brokerages have recently weighed in on RTRX. Wedbush began coverage on Travere Therapeutics in a research report on Thursday, September 17th. They set an “outperform” rating and a $33.00 price objective for the company. BMO Capital Markets raised their price objective on Travere Therapeutics from $31.00 to $33.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. TheStreet upgraded Travere Therapeutics from a “d+” rating to a “c-” rating in a research report on Tuesday, November 17th. BidaskClub upgraded Travere Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, November 29th. Finally, Zacks Investment Research lowered Travere Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, October 24th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $27.43.
About Travere Therapeutics
Travere Therapeutics, Inc is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.
Further Reading: What strategies should day traders use to execute a trade?
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Travere Therapeutics, Inc. (NASDAQ:RTRX).
Receive News & Ratings for Travere Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.